Investigación clínica y traslacional en enfermedades hepáticas y digestivas - SeLiver Group

A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients

COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic

Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain

Effectiveness and safety of obeticholic acid in a Southern European multicenter cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid

Exploration of piperazine-derived thioureas as antibacterial and anti-inflammatory agents. In vitro evaluation against clinical isolates of colistin-resistant Acinetobacter baumannii

Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes

Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study

Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice

Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus

International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

Loss of GATA4 causes ectopic pancreas in the stomach

Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts

Megacolon in inflammatory bowel disease: response to infliximab

Negative predictive value of the repeated absence of gluten immunogenic peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-up in celiac disease

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice

Optimization of piperazine-derived ureas privileged structures for effective antiadenovirus agents

Oral glutamine challenge is a marker of altered ammonia metabolism and predicts the risk of hepatic encephalopathy

Overall clinical and economic impact of non-alcoholic fatty liver disease

Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease

Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Severe enterocolitis secondary to ipilimumab and nivolumab with an excellent response to a single dose of infliximab

Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

Tacrolimus as an Effective and Durable Second-Line Treatment for Chronic Autoimmune Hepatitis: A Multicentric Study

Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology

The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management

Variation in Colonoscopy Performance Measures According to Procedure Indication

When DNA gets in the way: A cautionary note for DNA contamination in extracellular RNA-seq studies

qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis

A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy.

A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR.

A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms.

Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH.

Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria.

Cardiotrophin-1 is an anti-inflammatory cytokine and promotes IL-4-induced M2 macrophage polarization.

Does the Antitumor Necrosis Factor-α Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?

Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease.

Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.

Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH).

Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). (1)

Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis.

Hepatic encephalopathy and traffic accidents: Vigilance is needed!

Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).

Impaired brain glymphatic flow in experimental hepatic encephalopathy.

Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models.

Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.

Pancreatobiliary maljunction: association with gallbladder cancer.

Phospho-RNA-seq: a modified small RNA-seq method that reveals circulating mRNA and lncRNA fragments as potential biomarkers in human plasma.

Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study.

Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis.

Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis.

Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.

Relationship Between Self-Perceived Health, Vitality, and Posttraumatic Growth in Liver Transplant Recipients.

Relationship between the endothelial dysfunction and the expression of the β1-subunit of BK channels in a non-hypertensive sleep apnea group.

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.

Use of Steatotic Grafts in Liver Transplantation: Current Status.

Usefulness of bioelectrical impedance analysis for monitoring patients with refractory ascites.

Water-soluble extracts from edible mushrooms (Agaricus bisporus) as inhibitors of hepatitis C viral replication.

qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.

Colangitis biliar primaria en España. Resultados de un estudio Delphi sobre su epidemiología, diagnóstico, seguimiento y tratamiento.

Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline.

Consumption of orange fermented beverage improves antioxidant status and reduces peroxidation lipid and inflammatory markers in healthy humans.

Crohn's disease and cystic fibrosis: there is still a lot to learn

Diagnostic accuracy of SCCA and SCCA-IgM for hepatocellular carcinoma: A meta-analysis.

Editorial: looking for patients at risk of cirrhosis in the general population-many needles in a haystack

Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.

El impacto del tratamiento de la encefalopatía hepática mínima en el pronóstico a largo plazo.

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.

Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD).

Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation

Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience

Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry.

High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries

IgG4-related sclerosing mesenteritis, a rare condition that causes abdominal pain.

Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C.

Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts.

Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy.

Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. Ampuero

Mobile Health Solutions for Hypertensive Disorders in Pregnancy: Scoping Literature Review.

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030

Modulation of faecal metagenome in Crohn's disease: Role of microRNAs as biomarkers

Natural Extracts Abolished Lipid Accumulation in Cells Harbouring non-favourable PNPLA3 genotype.

New therapeutic perspectives in non-alcoholic steatohepatitis

Peer-to-Peer Sessions in Primary Care to Improve the Hepatitis B Detection Rate in Seville, Spain.

Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment.

Simvastatin and metformin inhibited cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.

The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.

Topical mesalazine as a cause of Stevens-Johnson syndrome

miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations.

Meta-analysis: pegylated interferon α-2a achieves higher early virological responses than α-2b in chronic hepatitis C.

Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study.

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.

Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.

Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C.

Value of the critical flicker frequency in patients with minimal hepatic encephalopathy.

Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.